In Reply Dr Keller correctly cites the Food and Drug Administration safety communication regarding the 80-mg dose of simvastatin as a factor that may have influenced the prescribing of that agent relative to Lipitor (atorvastatin calcium; Pfizer Inc). The June 8, 2011, safety communication was preceded by an earlier notice on March 19, 2010, regarding the possibility that 80-mg simvastatin was associated with an increased risk of muscle injury relative to other drugs in the statin class. However, in the years leading up to these safety communications during which less-expensive generic simvastatin products were available (ie, 2007-2009), Lipitor was not only the most commonly prescribed statin, surpassing generic simvastatin, but also the most commonly prescribed drug, surpassing all other prescription drugs.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Alldredge BK, Kayser SR. Why Physicians Favored Lipitor Over Simvastatin—Reply. JAMA Intern Med. 2013;173(15):1473. doi:10.1001/jamainternmed.2013.7701
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.